ZEO ScientifiX Launches Physician-Focused Masterclass Ahead of Florida's SB-1768 Law Implementation
ZEO ScientifiX (OTCQB:ZEOX) has announced the launch of ZEO Masterclass, a physician-focused educational initiative ahead of Florida's SB-1768 law implementation on July 1, 2025. The new law will allow licensed MDs and DOs to offer non-FDA-approved stem cell therapies for specific medical indications under strict compliance protocols.
The four-hour intensive training will be held on June 27th at NOVA Southeastern University, covering legal compliance, clinical integration, and scientific insights for stem cell and exosome therapies. The program aims to prepare physicians for implementing regenerative therapies in areas including pain management, wound healing, and orthopedics.
ZEO ScientifiX (OTCQB:ZEOX) ha annunciato il lancio di ZEO Masterclass, un'iniziativa educativa rivolta ai medici in vista dell'entrata in vigore della legge SB-1768 della Florida il 1° luglio 2025. La nuova normativa permetterà ai medici autorizzati MD e DO di offrire terapie con cellule staminali non approvate dalla FDA per specifiche indicazioni mediche, rispettando protocolli rigorosi.
La formazione intensiva di quattro ore si terrà il 27 giugno presso la NOVA Southeastern University e affronterà temi quali la conformità legale, l'integrazione clinica e le conoscenze scientifiche sulle terapie con cellule staminali ed esosomi. Il programma è pensato per preparare i medici all'implementazione di terapie rigenerative in ambiti come la gestione del dolore, la guarigione delle ferite e l'ortopedia.
ZEO ScientifiX (OTCQB:ZEOX) ha anunciado el lanzamiento de ZEO Masterclass, una iniciativa educativa dirigida a médicos antes de la implementación de la ley SB-1768 de Florida el 1 de julio de 2025. La nueva ley permitirá a médicos licenciados MD y DO ofrecer terapias con células madre no aprobadas por la FDA para indicaciones médicas específicas bajo estrictos protocolos de cumplimiento.
La capacitación intensiva de cuatro horas se realizará el 27 de junio en la Universidad NOVA Southeastern, cubriendo cumplimiento legal, integración clínica y conocimientos científicos sobre terapias con células madre y exosomas. El programa busca preparar a los médicos para implementar terapias regenerativas en áreas como el manejo del dolor, la cicatrización de heridas y la ortopedia.
ZEO ScientifiX (OTCQB:ZEOX)는 플로리다주 SB-1768 법안 시행을 앞두고 의사 대상 교육 프로그램인 ZEO 마스터클래스를 출시했다고 발표했습니다. 새로운 법은 2025년 7월 1일부터 면허가 있는 MD 및 DO 의사들이 특정 의료 적응증에 대해 FDA 승인받지 않은 줄기세포 치료를 엄격한 준수 프로토콜 하에 제공할 수 있도록 허용합니다.
4시간 집중 교육은 6월 27일 NOVA Southeastern 대학교에서 진행되며, 법적 준수, 임상 통합, 줄기세포 및 엑소좀 치료에 대한 과학적 통찰을 다룹니다. 이 프로그램은 통증 관리, 상처 치유, 정형외과 등 재생 치료를 시행할 의사들을 준비시키는 것을 목표로 합니다.
ZEO ScientifiX (OTCQB:ZEOX) a annoncé le lancement de ZEO Masterclass, une initiative éducative destinée aux médecins en prévision de la mise en œuvre de la loi SB-1768 de Floride le 1er juillet 2025. Cette nouvelle loi permettra aux médecins titulaires d'un MD ou DO d'offrir des thérapies à base de cellules souches non approuvées par la FDA pour des indications médicales spécifiques, sous des protocoles de conformité stricts.
La formation intensive de quatre heures aura lieu le 27 juin à l'université NOVA Southeastern et couvrira la conformité légale, l'intégration clinique et les connaissances scientifiques sur les thérapies par cellules souches et exosomes. Le programme vise à préparer les médecins à la mise en œuvre de thérapies régénératives dans des domaines tels que la gestion de la douleur, la cicatrisation des plaies et l'orthopédie.
ZEO ScientifiX (OTCQB:ZEOX) hat die Einführung der ZEO Masterclass bekannt gegeben, einer auf Ärzte ausgerichteten Bildungsinitiative im Vorfeld der Umsetzung des SB-1768 Gesetzes in Florida am 1. Juli 2025. Das neue Gesetz erlaubt lizenzierten MDs und DOs, nicht von der FDA zugelassene Stammzelltherapien für bestimmte medizinische Indikationen unter strikten Compliance-Protokollen anzubieten.
Das vierstündige Intensivtraining findet am 27. Juni an der NOVA Southeastern University statt und behandelt rechtliche Compliance, klinische Integration sowie wissenschaftliche Erkenntnisse zu Stammzell- und Exosomentherapien. Das Programm soll Ärzte darauf vorbereiten, regenerative Therapien in Bereichen wie Schmerzbehandlung, Wundheilung und Orthopädie einzusetzen.
- New Florida law creates commercial opportunities for ZEO's stem cell products
- Company positioned as trusted source with FDA-registered facility
- Strategic educational initiative to capture market share ahead of law implementation
- Products still require strict compliance with new regulatory framework
- Limited to Florida market initially
- Operating without permanent CEO (interim CEO in place)
FORT LAUDERDALE, FL / ACCESS Newswire / June 24, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company pioneering the research and development of innovative biological therapeutics, has announced their upcoming ZEO Masterclass - a physician-led initiative designed to educate Florida doctors on one of the most significant regulatory changes in recent healthcare history.
The New Frontier in Regenerative Medicine
With Florida's SB-1768 law ("Law") set to take effect on July 1, 2025, licensed MDs and DOs will, for the first time in accordance with the terms of the Law, be authorized to offer non-FDA-approved stem cell therapies directly to patients in defined medical indications and only if conducted under strict compliance protocols. This legislative breakthrough introduces transformative potential across multiple specialties, including:
Pain Management
Wound Healing
Orthopedics
While this Law opens clinical and commercial doors to ZEO that, until now, have previously been unavailable unless such products were FDA approved, it also presents a complex and unfamiliar landscape for physicians who will be obligated to comply with the regulations outlined under the Law. That is why ZEO is stepping in to serve as a bridge between this groundbreaking legislation and responsible, compliant medical practice.
"As a company with deep roots in Florida, a strong research foundation and an FDA-registered facility, we are uniquely positioned to be the state's most trusted source for safe, high-quality stem cell products that are within the guidelines of the new law," said Ian Bothwell, interim chief executive officer of ZEO ScientifiX. "We're proud to support physicians in their desire to incorporate innovative solutions that meet the highest standards of science, ethics and patient care."
The ZEO Masterclass: Designed for Today's Physician-Pioneers
Unlike any other offering in the field, the ZEO Masterclass is a four-hour intensive training created specifically for physicians ready to lead this new era of regenerative medicine. From legal compliance to clinical integration, the curriculum delivers:
A clear interpretation of SB-1768
Real-world applications for stem cell and exosome therapies
Scientific insights backed by ZEO's biologics R&D expertise
Ethical guidelines and safety frameworks
Attendees will receive direct instruction from leading experts in biologics and compliance - equipping them to implement regenerative therapies responsibly and confidently.
Upcoming Event Details
ZEO Masterclass on Stem Cells & Exosomes
Date: Friday June 27th
Time: 9:00 AM - 2:00 PM (Lunch Included)
Location: Alvin Sherman Library, 5th Floor
Address: 3100 Ray Ferrero Jr Blvd, Davie, FL 33314
Hosted at NOVA Southeastern University, South Florida
Physicians ready to lead the future of healthcare can register now at ZEO's website or contact info@zeoscientifix.com for more information.
About ZEO ScientifiX, Inc.
ZEO is not just keeping pace with regulatory change - we're setting the standard. As a clinical-stage biopharmaceutical company focused on the development of biological therapeutic platforms, we believe that when physicians are educated, patients are better served - and innovation thrives. We are driven by a commitment to advance the frontiers of regenerative medicine and biologic therapeutics, delivering meaningful solutions for patients and providers worldwide. Our proprietary products, including (a) Zofin™, which are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and (b) Patient Pure X™ ("PPX™"), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood. During November 2024, the Company announced that it was launching the first planned collaborative product with Exotropin; "ZEO HAIR GROW™ Powered By Exotropin™", a proprietary topical physician formulated hair regrow system. The Company's proprietary products are manufactured in an FDA-registered, cGMP-compliant laboratory. To learn more, please visit https://zeoscientifix.com.
Forward-Looking Statements
Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will," "believes," "expects," "potential," or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. No assurances can be given that the Florida Stem Cell Law will be beneficial to the Company or any initiatives related to this new law will increase the price of our common stock to a level that is attractive to brokerage houses and institutional investors. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations, including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. ZEO has no intention and specifically disclaims any duty to update the information in this press release.
Contact Information
Chloe Detrick
Plus4 Public Relations
chloe@plus4pr.com
SOURCE: Zeo ScientifiX, Inc.
View the original press release on ACCESS Newswire
FAQ
What is Florida's SB-1768 law and when does it take effect for ZEOX?
What medical areas will ZEO ScientifiX (ZEOX) target with their stem cell therapies?
When and where is the ZEO ScientifiX (ZEOX) Masterclass being held?
What will physicians learn in the ZEOX Masterclass program?
Who is currently leading ZEO ScientifiX (ZEOX)?
